Y-mAbs Therapeutics IncNASDAQ:YMAB
- LAST PRICE15.0000
- TODAY'S CHANGE (%)-0.1100 (-0.7280%)
- Bid / Lots11.0000/ 4
- Ask / Lots17.3800/ 1
- Open / Previous Close14.9300 / 15.1100
- Day Range
- 52 Week Range
- Volume410,152
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | YMAB |
|---|---|---|
| 09:32 ET | 8261 | 15.04 |
| 09:34 ET | 830 | 15.015 |
| 09:38 ET | 300 | 15.03 |
| 09:39 ET | 300 | 15.03 |
| 09:41 ET | 200 | 15.11 |
| 09:43 ET | 500 | 15.01 |
| 09:45 ET | 1200 | 14.91 |
| 09:48 ET | 9391 | 14.94 |
| 09:50 ET | 15324 | 14.8215 |
| 09:52 ET | 5915 | 15 |
| 09:54 ET | 100 | 15.04 |
| 09:56 ET | 300 | 15.05 |
| 09:57 ET | 100 | 15.13 |
| 09:59 ET | 600 | 15.12 |
| 10:01 ET | 900 | 15.13 |
| 10:03 ET | 300 | 15.12 |
| 10:06 ET | 830 | 15.13 |
| 10:08 ET | 500 | 15.18 |
| 10:10 ET | 200 | 15.21 |
| 10:12 ET | 300 | 15.2899 |
| 10:14 ET | 200 | 15.26 |
| 10:15 ET | 200 | 15.33 |
| 10:17 ET | 100 | 15.28 |
| 10:19 ET | 300 | 15.36 |
| 10:24 ET | 500 | 15.37 |
| 10:26 ET | 300 | 15.37 |
| 10:28 ET | 100 | 15.37 |
| 10:32 ET | 882 | 15.31 |
| 10:33 ET | 600 | 15.25 |
| 10:35 ET | 300 | 15.25 |
| 10:37 ET | 1110 | 15.26 |
| 10:39 ET | 200 | 15.34 |
| 10:44 ET | 1300 | 15.42 |
| 10:46 ET | 208 | 15.36 |
| 10:48 ET | 100 | 15.44 |
| 10:50 ET | 400 | 15.46 |
| 10:51 ET | 886 | 15.36 |
| 10:53 ET | 1050 | 15.33 |
| 10:55 ET | 1425 | 15.23 |
| 11:00 ET | 300 | 15.115 |
| 11:02 ET | 1530 | 15.125 |
| 11:04 ET | 1000 | 15.13 |
| 11:06 ET | 2556 | 15.2 |
| 11:08 ET | 1229 | 15.2768 |
| 11:09 ET | 100 | 15.35 |
| 11:11 ET | 100 | 15.34 |
| 11:13 ET | 1300 | 15.29 |
| 11:15 ET | 300 | 15.35 |
| 11:18 ET | 294 | 15.35 |
| 11:20 ET | 334 | 15.31 |
| 11:24 ET | 100 | 15.35 |
| 11:27 ET | 774 | 15.3 |
| 11:31 ET | 100 | 15.23 |
| 11:33 ET | 100 | 15.27 |
| 11:36 ET | 800 | 15.2689 |
| 11:38 ET | 2337 | 15.265 |
| 11:42 ET | 100 | 15.29 |
| 11:44 ET | 200 | 15.245 |
| 11:45 ET | 800 | 15.24 |
| 11:47 ET | 543 | 15.28 |
| 11:49 ET | 250 | 15.26 |
| 11:54 ET | 100 | 15.26 |
| 11:58 ET | 400 | 15.23 |
| 12:00 ET | 833 | 15.185 |
| 12:02 ET | 5350 | 15.335 |
| 12:03 ET | 169 | 15.34 |
| 12:07 ET | 1200 | 15.3 |
| 12:09 ET | 400 | 15.28 |
| 12:12 ET | 600 | 15.29 |
| 12:14 ET | 833 | 15.29 |
| 12:16 ET | 200 | 15.3 |
| 12:18 ET | 100 | 15.32 |
| 12:20 ET | 500 | 15.3 |
| 12:21 ET | 539 | 15.26 |
| 12:25 ET | 269 | 15.22 |
| 12:27 ET | 150 | 15.24 |
| 12:30 ET | 700 | 15.27 |
| 12:32 ET | 329 | 15.27 |
| 12:36 ET | 400 | 15.33 |
| 12:38 ET | 200 | 15.34 |
| 12:39 ET | 100 | 15.36 |
| 12:41 ET | 454 | 15.31 |
| 12:43 ET | 400 | 15.27 |
| 12:45 ET | 7024 | 15.355 |
| 12:48 ET | 200 | 15.37 |
| 12:50 ET | 603 | 15.32 |
| 12:52 ET | 700 | 15.3 |
| 12:54 ET | 526 | 15.22 |
| 12:56 ET | 200 | 15.27 |
| 12:57 ET | 100 | 15.3 |
| 12:59 ET | 150 | 15.3 |
| 01:03 ET | 129 | 15.31 |
| 01:06 ET | 200 | 15.28 |
| 01:10 ET | 200 | 15.255 |
| 01:12 ET | 1352 | 15.26 |
| 01:14 ET | 614 | 15.25 |
| 01:15 ET | 200 | 15.21 |
| 01:17 ET | 2100 | 15.2 |
| 01:19 ET | 2623 | 15.29 |
| 01:21 ET | 200 | 15.3 |
| 01:24 ET | 600 | 15.25 |
| 01:26 ET | 1436 | 15.25 |
| 01:28 ET | 1600 | 15.25 |
| 01:32 ET | 1450 | 15.27 |
| 01:33 ET | 500 | 15.26 |
| 01:35 ET | 1628 | 15.26 |
| 01:37 ET | 1600 | 15.2215 |
| 01:42 ET | 100 | 15.24 |
| 01:44 ET | 2525 | 15.24 |
| 01:46 ET | 100 | 15.23 |
| 01:48 ET | 100 | 15.27 |
| 01:50 ET | 200 | 15.28 |
| 01:51 ET | 100 | 15.2837 |
| 01:53 ET | 200 | 15.3 |
| 01:55 ET | 100 | 15.31 |
| 01:57 ET | 200 | 15.3 |
| 02:00 ET | 380 | 15.31 |
| 02:02 ET | 100 | 15.3 |
| 02:04 ET | 1895 | 15.24 |
| 02:06 ET | 500 | 15.24 |
| 02:09 ET | 750 | 15.215 |
| 02:11 ET | 2300 | 15.235 |
| 02:13 ET | 8043 | 15.215 |
| 02:15 ET | 400 | 15.22 |
| 02:18 ET | 1100 | 15.25 |
| 02:20 ET | 100 | 15.24 |
| 02:22 ET | 800 | 15.22 |
| 02:24 ET | 2162 | 15.23 |
| 02:27 ET | 359 | 15.228 |
| 02:29 ET | 2150 | 15.22 |
| 02:31 ET | 800 | 15.19 |
| 02:33 ET | 16049 | 15.15 |
| 02:36 ET | 4902 | 15.21 |
| 02:38 ET | 1242 | 15.205 |
| 02:40 ET | 904 | 15.17 |
| 02:42 ET | 2200 | 15.18 |
| 02:45 ET | 220 | 15.19 |
| 02:47 ET | 499 | 15.15 |
| 02:49 ET | 4281 | 15.17 |
| 02:51 ET | 4626 | 15.16 |
| 02:54 ET | 200 | 15.145 |
| 02:56 ET | 900 | 15.19 |
| 02:58 ET | 200 | 15.23 |
| 03:00 ET | 77079 | 15.2 |
| 03:07 ET | 200 | 15.21 |
| 03:09 ET | 1639 | 15.16 |
| 03:12 ET | 1361 | 15.08 |
| 03:14 ET | 1100 | 15.04 |
| 03:16 ET | 1233 | 15.125 |
| 03:18 ET | 300 | 15.13 |
| 03:20 ET | 600 | 15.065 |
| 03:21 ET | 328 | 15.01 |
| 03:23 ET | 100 | 15.06 |
| 03:25 ET | 600 | 15.08 |
| 03:27 ET | 100 | 15.11 |
| 03:30 ET | 200 | 15.1 |
| 03:32 ET | 10595 | 15.17 |
| 03:34 ET | 300 | 15.2 |
| 03:36 ET | 700 | 15.21 |
| 03:38 ET | 1500 | 15.22 |
| 03:39 ET | 1850 | 15.1 |
| 03:43 ET | 828 | 15.1 |
| 03:45 ET | 1154 | 15.11 |
| 03:48 ET | 525 | 15.035 |
| 03:50 ET | 400 | 14.985 |
| 03:52 ET | 537 | 14.97 |
| 03:54 ET | 2063 | 15.04 |
| 03:56 ET | 3278 | 14.97 |
| 03:57 ET | 2463 | 14.99 |
| 03:59 ET | 4438 | 15 |
Apr 2, 2024
DJ Y-mAbs Therapeutics Down Nearly 11%, on Pace for Largest Percent Decrease Since November 2022 -- Data Talk, from 2:04PM ET on Tuesday Apr 02, 2024 by Dow Jones
2:04PM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Y-mAbs Therapeutics Inc | 661.5M | -30.6x | --- |
Zymeworks Inc | 624.5M | -5.0x | --- |
CureVac NV | 575.5M | -1.6x | --- |
SAGE Therapeutics Inc | 755.5M | -1.4x | --- |
Fate Therapeutics Inc | 596.4M | -3.1x | --- |
Urogen Pharma Ltd | 485.9M | -3.8x | --- |
Company Information
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Contact Information
- Headquarters
- 230 PARK AVENUE, SUITE 3350NEW YORK, NY, United States 10169
- Phone
- 212-847-9841
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- James Healy
- President, Chief Executive Officer, Director
- Michael Rossi
- Vice Chairman of the Board, Chief Business Officer
- Thomas Gad
- Chief Financial Officer, Executive Vice President, Treasurer, Secretary
- Bo Kruse
- Chief Operating Officer, Senior Vice President
- Joris Wilms
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $661.5M |
|---|---|
Revenue (TTM) | $84.8M |
Shares Outstanding | 43.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-0.49 |
Book Value | $2.31 |
P/E Ratio | -30.6x |
Price/Sales (TTM) | 7.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -30.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
